Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections

被引:87
作者
Buijk, SLCE
Gyssens, IC
Mouton, JW
Van Vliet, A
Verbrugh, HA
Bruining, HA
机构
[1] Erasmus Univ, Med Ctr, Dept Surg Intens Care, Rotterdam, Netherlands
[2] Erasmus Univ, Med Ctr, Dept Med Microbiol & Infect Dis, Rotterdam, Netherlands
[3] Canisius Wilhelmina Hosp, Dept Med Microbiol & Infect Dis, Nijmegen, Netherlands
关键词
D O I
10.1093/jac/49.1.121
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Ceftazidime demonstrates time-dependent killing, which is maximal at 4 x or 5 x MIC for the organism, consequently continuous infusion (CI) has been proposed to ensure adequate ceftazidime concentrations for the entire course of therapy. Severe intra-abdominal infections (IAIs) require surgical or percutaneous drainage for management, and ceftazidime is frequently prescribed. Cardiovascular or metabolic changes and renal or liver dysfunction may alter drug pharmacokinetics during severe IAIs, and no data exist on concentrations of ceftazidime reached in the peritoneal fluid. The objectives here were to determine the pharmacokinetics of ceftazidime during continuous and intermittent administration in patients with severe IAIs, and to measure the concentrations of ceftazidime in the peritoneal exudate. Eighteen surgical patients with severe IAI and a creatinine clearance of >30 mL/min were studied. A non-randomized pilot study of six patients treated with CI alone was followed by a prospective, randomized comparative study of 12 patients. Pilot study patients received ceftazidime 1 g iv followed by a 4.5 g CI over 24 h. Randomized patients received either ceftazidime continuously as above or 1.5 g tds. Samples for pharmacokinetic analyses were collected on days 2 and 4. Ceftazidime concentrations were determined by high-performance liquid chromatography. CI resulted in a mean serum concentration >40 mg/L and a T > 4 x MIC for most pathogens encountered in severe IAIs for >90% of the course of therapy in both serum and peritoneal exudate. Eight-hourly administration resulted in T > 4 x MIC for most pathogens encountered in severe IAIs for >90% of the dosing interval, but in peritoneal exudate for only 44% of the dosing interval. During CI, AUCs in the peritoneal exudate were c. 60% of the concomitant serum AUCs. In critically ill surgical patients with severe IAIs, CI of ceftazidime resulted in more favourable concentrations in serum and peritoneal exudate than 8-hourly bolus infusion.
引用
收藏
页码:121 / 128
页数:8
相关论文
共 27 条
[2]   Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections [J].
Benko, AS ;
Cappelletty, DM ;
Kruse, JA ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (03) :691-695
[3]  
BOHNEN JMA, 1992, ARCH SURG-CHICAGO, V127, P83
[4]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[5]   THE PENETRATION OF CEFTAZIDIME INTO PERITONEAL-FLUID IN PATIENTS UNDERGOING ELECTIVE ABDOMINAL-SURGERY [J].
CORBETT, CRR ;
MCFARLAND, RJ ;
SPENDER, GR ;
RYAN, DM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1985, 16 (02) :261-265
[6]   INTERRELATIONSHIP BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS IN DETERMINING DOSAGE REGIMENS FOR BROAD-SPECTRUM CEPHALOSPORINS [J].
CRAIG, WA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 22 (1-2) :89-96
[7]   CONTINUOUS INFUSION OF BETA-LACTAM ANTIBIOTICS [J].
CRAIG, WA ;
EBERT, SC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (12) :2577-2583
[8]  
DENHOLLANDER JG, 1997, 20 INT C CHEM SYDN, P72
[9]   CEFTAZIDIME - ASPECTS OF EFFICACY AND TOLERANCE [J].
FOORD, RD .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1983, 12 :399-403
[10]   Population pharmacokinetics of continuous infusion ceftazidime [J].
Frame, BC ;
Facca, BF ;
Nicolau, DP ;
Triesenberg, SN .
CLINICAL PHARMACOKINETICS, 1999, 37 (04) :343-350